After BioCryst fizzle, a new oral HAE player emerges

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 10, 2019 at 11:13 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via A new player in the search for an oral hereditary angioedema pill has received a major boost and show of confidence.

    Pharvaris announced $66 million in Series B financing for its B2 receptor antagonist pill, nearly tripling the funding Attune Pharmaceuticals recently received in Series B for its own hereditary angioedema (HAE) pill. The money will fuel the company’s Phase 1 trial on its lead compound, PHAp121, on healthy volunteers. The first subjects have already been dosed.

    article source